KEY OPINION LEADERS REVIEW CASE SCENARIOS IN TARGETED ONCOLOGYTM LIVE DISCUSSIONS
PD-L1 Status Affects Physician’s Choice of Treatment in Lung Cancer
February 13th 2021For the treatment of patients with lung cancer and low PD-L1 expression, immunotherapy-based combinations have been shown effective through clinical trial research. Stephen Liu, MD, reviewed the studies during a Targeted Oncology Case-Based Peer Perspectives virtual event.
Expert Discusses HER2 Selective Kinase Inhibitors in Heavily Pretreated Breast Cancer
February 8th 2021During a Targeted Oncology Case-Based Peer Perspectives virtual event, Lee Schwartzberg, MD, medical oncologist, West Cancer Center and Research Institute, discussed the therapeutic options for a 39-year-old woman with HER2-positive breast cancer who was heavily pretreated.
Multikinase Inhibitor Options Flourish for Patients With RET-Mutant Medullary Thyroid Cancer
February 4th 2021During a Targeted Oncology Case-Based Peer Perspectives event, Andrew G. Gianoukakis, MD, FACE, discussed the use of multikinase inhibitors for RET-mutated medullary thyroid cancer.
Use of Anthracycline or Nonanthracycline Therapy Is Considered in HER2+ Breast Cancer
February 3rd 2021During a Targeted Oncology Case-Based Peer Perspectives event, Sara M. Tolaney, MD, MPH, discussed therapies available for the treatment of a 42-year-old woman with HER2-positive breast cancer.
Rabinowits Analyzes the Use of Anti–PD-1 Therapy in cSCC
February 1st 2021During a Targeted Oncology Case-Based Peer Perspectives event, Guilherme Rabinowits, MD, medical oncologist/hematologist, Miami Cancer Institute, discussed the case of 69-year-old patients with cutaneous squamous cell carcinoma.
Physicians Have Multiple Choices of Treatment in the Nonmetastatic CRPC Setting
January 31st 2021During a Targeted Oncology Case-Based Peer Perspectives Roundtable, Tanya Dorff, MD, reviews the available treatment options for nonmetastatic castration-resistant prostate cancer to select a treatment for 57-year-old patient.